Inhibition of human recombinant MAGL using 1,3-dihydroxypropan-1-yl 4-pyren-1-yl butanoate as substrate at 10 uM preincubated for 15 mins with substrate followed by protein addition measured after 45 mins by reverse phase HPLC with fluorescence detection method
Inhibition of human recombinant MAGL using 1,3-dihydroxypropan-1-yl 4-pyren-1-yl butanoate as substrate preincubated for 15 mins with substrate followed by protein addition measured after 45 mins by reverse phase HPLC with fluorescence detection method
Enzyme Assay: All rate-based assays were performed in black 384-well polypropylene polymerase chain reaction (PCR) microplates (Abgene) in a total volume of 30 μL. Substrate 4-methylumbelliferyl butyrate (4MU-B; Sigma) and either purified mutant MGL (mut-MGLL 11-313 L179S L186S) or purified wild type MGL (wt-MGLL 6H-11-313) were diluted separately into 20 mM PIPES buffer (pH=7.0), containing 150 mM NaCl and 0.001% Tween 20. Compounds of formula (I) were pre-dispensed (50 nL) into the microplate using a liquid handling dispenser prior to adding 4MU-B (25 μL of 1.2× solution to a final concentration of 10 μM) followed by enzyme (5 μL of a 6× solution to a final concentration of 5 nM) to initiate the reaction. Final compound concentrations ranged from 17 to 0.0003 μM. The fluorescence change due to 4MU-B cleavage was monitored with excitation and emission wavelengths of 335 and 440 nm, respectively, and a bandwidth of 10 nm (Safire2, Tecan) at 37° C. for 5 min.
ThermoFluor Assay: The ThermoFluor (TF) assay is a 384-well microplate-based binding assay that measures thermal stability of proteins1,2. The experiments were carried out using ThermoFluor instruments available from Johnson & Johnson Pharmaceutical Research & Development, LLC. TF dye used in all experiments was 1,8-ANS (Invitrogen: A-47). Final TF assay conditions used for MGL studies were 0.07 mg/ml of mutant MGL, 100 uM ANS, 200 mM NaCl, 0.001% Tween-20 in 50 mM PIPES (pH=7.0).Screening compound plates contained 100% DMSO compound solutions at a single concentration. For follow-up concentration-response studies, compounds were arranged in a pre-dispensed plate (Greiner Bio-one: 781280), wherein compounds were serially diluted in 100% DMSO across 11 columns within a series. Columns 12 and 24 were used as DMSO reference and contained no compound. For both single and multiple compound concentration-repsonse experiments, the compound aliquots (46 mL) were robotically predispensed directly into 384-well.
Inhibition of human MGL expressed in HEK239 cells using 2AG as substrate assessed as residual activity at 10 uM preincubated for 10 mins followed by substrate addition measured after 10 mins by HPLC analysis
Inhibition of recombinant C-terminal His6-tagged human MAGL expressed in Escherichia coli using 2-arachidonoyl-[3H]-glycerol as substrate incubated for 20 mins by scintillation counting method
Inhibition of human MAGL expressed in African green monkey COS cells using 2-arachidonoyl-[3H]-glycerol as substrate incubated for 20 mins by scintillation counting method
Inhibition of recombinant C-terminal His6-tagged human MAGL expressed in Escherichia coli using 2-arachidonoyl-[3H]-glycerol as substrate preincubated for 10 mins followed by substrate addition measured after 20 mins by scintillation counting method